Guangdong Hengrui Pharmaceutical Co., Ltd

This study tests a new inhaled drug called HRS-9821 in people with moderate to severe COPD. About 90 participants will receive either the drug or a placebo for 28 days. The main goal is to see if the drug improves lung function, measured by how much air they can exhale in one sec…

This study tests whether SHR-2173, added to usual care, improves symptoms of generalized myasthenia gravis (gMG) better than a placebo. About 60 adults with confirmed gMG will receive the drug or placebo for 24 weeks. The main goal is to see if daily muscle weakness and fatigue s…

This early-stage study tests an inhaled powder called HRS-9821 in healthy volunteers and people with COPD. The main goal is to check safety and how the body handles the drug. About 48 participants will receive either the drug or a placebo.

This phase 2 study tests an injection called SHR-1139 in 20 adults with pyoderma gangrenosum, a rare condition causing painful skin ulcers. The goal is to see if the drug can completely close the ulcers and how safe it is. Researchers will also measure how the body processes the …